Concourse Financial Group Securities, Inc. Trevi Therapeutics, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.64 Billion
- Q3 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding TRVI
# of Institutions
76Shares Held
54.4MCall Options Held
15.6KPut Options Held
0-
Nea Management Company, LLC Timonium, MD11.4MShares$33 Million3.2% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.38MShares$21.4 Million1.3% of portfolio
-
Rubric Capital Management LP New York, NY5.03MShares$14.6 Million0.44% of portfolio
-
Viking Global Investors LP4.4MShares$12.8 Million0.05% of portfolio
-
Vr Adviser, LLC New York, NY3.42MShares$9.93 Million1.12% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $169M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...